Jimmy Swan, MD
Cardiovascular Disease · Tacoma, WANPI 1447363734
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 74.6% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2020 at $9,142 and has fallen 95.8% since, to $385 in 2025. Among cardiovascular disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 510 payments — averaging $55.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$21K
- Edwards Lifesciences$2K
- Abiomed$909
- Amgen$821
- AstraZeneca$778
- Boston Scientific$465
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$16,00056%
- Travel & lodging$2,90710%
- Food & beverage$9,44733%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 257 | $21,178 |
| Edwards Lifesciences | 12 | $1,894 |
| Abiomed | 50 | $909 |
| Amgen | 34 | $821 |
| AstraZeneca | 44 | $778 |
| Boston Scientific | 13 | $465 |
| Abbott | 12 | $447 |
| Boehringer Ingelheim | 13 | $320 |
| Novartis | 18 | $309 |
| E.r. Squibb & Sons, L.L.C. | 10 | $190 |
| Pfizer | 8 | $163 |
| Regeneron Healthcare Solutions, Inc. | 7 | $133 |
| Otsuka America Pharmaceutical, Inc. | 6 | $121 |
| Cook Medical LLC | 1 | $95 |
| Johnson & Johnson | 6 | $94 |
| Biotronik Inc. | 4 | $89 |
| Stryker | 1 | $87 |
| Chiesi USA, Inc. | 4 | $74 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Angiodynamics, Inc. | 1 | $49 |
| Biosense Webster, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Bayer | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| BD | 1 | $18 |
| Heartflow, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$12,836
- COREVALVE EVOLUT R$5,265
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,695
- GENERAL VASCULAR ACCESS$124
- JARDIANCE$119
- Impella$117
- ONYX FRONTIER$104
How this compares
$28,389 in reported general payments places this provider in the 95th percentile of 370 cardiovascular disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 436 | $480,966 |
| XareltoRivaroxaban | 91 | $98,994 |
| EntrestoSacubitril/Valsartan | 87 | $82,537 |
| Repatha SureclickEvolocumab | 49 | $43,828 |
| FarxigaDapagliflozin Propanediol | 48 | $31,561 |
| Praluent PenAlirocumab | 22 | $28,269 |
| BrilintaTicagrelor | 48 | $28,095 |
| JardianceEmpagliflozin | 18 | $21,789 |
| Repatha SyringeEvolocumab | 23 | $18,980 |
| Metoprolol Succinate | 729 | $13,246 |
| Atorvastatin Calcium | 441 | $4,954 |
| Ranolazine ErRanolazine | 48 | $4,945 |
| Losartan Potassium | 306 | $3,656 |
| ClopidogrelClopidogrel Bisulfate | 282 | $3,546 |
| Potassium Chloride | 127 | $2,989 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $163 | $480,966436 claims |
| Johnson & JohnsonXarelto | $94 | $98,99491 claims |
| NovartisEntresto | $309 | $82,53787 claims |
| AstraZenecaFarxiga, Brilinta | $778 | $59,65596 claims |
| Boehringer IngelheimJardiance | $320 | $21,78918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 370 cardiovascular disease providers in Washington.
Other cardiovascular disease in Tacoma
- Xuan GuanTacoma$12K
- Antony KimTacoma$8K
- Kurt KinneyTacoma$7K
- Raymond FisherTacoma$6K
- Robert BersinBellevue$657K
- Mariko HarperSeattle$246K
- Gary OppenheimSeattle$153K
- Kelley BranchSeattle$103K
- Munish Kumar KannabhiranRichland$85K
- Erik WissnerSeattle$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.